Security key
22663K107
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)
CUSIP: 22663K107
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 105,000,216
- Total 13F shares
- 104,559,713
- Share change
- +2,782,185
- Total reported value
- $3,007,383,972
- Put/Call ratio
- 25%
- Price per share
- $28.76
- Number of holders
- 220
- Value change
- +$75,026,414
- Number of buys
- 127
- Number of sells
- 102
Report period
Q2 2025
Institutions
220
Top holders
10
CRNX full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Crinetics Pharmaceuticals, Inc. SEC filings
Crinetics Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 22663K107
Recent filing periods:
Top shareholders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
15%
from 13D/G
|
14,031,269
|
$470,608,761 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.9%
|
9,311,600
|
$312,311,064 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.3%
|
7,656,569
|
$256,801,325 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
6.6%
|
6,891,397
|
$231,137,455 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
5.9%
|
6,239,902
|
$209,286,313 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,321,032
|
$200,336,855 | — | 18 Apr 2022 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
4.9%
|
5,112,360
|
$171,470,000 | — | 31 Mar 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.4%
|
4,605,098
|
$154,454,987 | — | 31 Mar 2025 | |
| EcoR1 Capital, LLC |
13F
|
Company |
4.1%
|
4,288,120
|
$143,823,545 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
3.3%
|
3,424,442
|
$118,895,467 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.1%
|
3,283,275
|
$110,121,044 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,190,932
|
$73,501,907 | — | 31 Mar 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
2%
|
2,119,767
|
$71,096,987 | — | 31 Mar 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.9%
|
1,946,168
|
$65,274,475 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.6%
|
1,688,611
|
$56,636,013 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.4%
|
1,500,000
|
$50,310,000 | — | 31 Mar 2025 | |
| Novo Holdings A/S |
13F
|
Company |
1.2%
|
1,275,000
|
$42,763,500 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1%
|
1,047,015
|
$35,116,883 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.95%
|
999,000
|
$33,506,460 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.92%
|
963,281
|
$32,308,444 | — | 31 Mar 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
0.88%
|
920,020
|
$30,858,000 | — | 31 Mar 2025 | |
| Hood River Capital Management LLC |
13F
|
Company |
0.83%
|
872,635
|
$29,268,178 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.82%
|
857,081
|
$28,746,497 | — | 31 Mar 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
0.81%
|
855,419
|
$28,690,753 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.74%
|
778,398
|
$26,107,469 | — | 31 Mar 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.74%
|
773,347
|
$25,938,057 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.72%
|
753,527
|
$25,273,296 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.69%
|
719,578
|
$24,134,665 | — | 31 Mar 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.66%
|
689,265
|
$23,118,000 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.6%
|
631,964
|
$21,196,073 | — | 31 Mar 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.58%
|
610,839
|
$20,487,000 | — | 31 Mar 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.57%
|
600,000
|
$20,124,000 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.5%
|
523,431
|
$17,555,875 | — | 31 Mar 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
0.5%
|
522,266
|
$17,517,000 | — | 31 Mar 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.49%
|
514,809
|
$17,266,694 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.49%
|
514,684
|
$17,262,501 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.48%
|
499,594
|
$16,756,383 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.47%
|
488,911
|
$16,398,075 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.54%
|
562,935
|
$15,862,926 | — | 31 Mar 2025 | |
| Fiera Capital Corp |
13F
|
Company |
0.42%
|
438,337
|
$14,701,823 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.41%
|
429,063
|
$14,390,773 | — | 31 Mar 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.34%
|
358,535
|
$12,025,264 | — | 31 Mar 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.33%
|
350,000
|
$11,739,000 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.33%
|
347,581
|
$11,657,867 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.33%
|
344,579
|
$11,557,195 | — | 31 Mar 2025 | |
| Universal- Beteiligungs- und Servicegesellschaft mbH |
13F
|
Individual |
0.33%
|
342,734
|
$11,495,299 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.3%
|
315,659
|
$10,587,203 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.29%
|
304,926
|
$10,227,224 | — | 31 Mar 2025 | |
| M&G Plc |
13F
|
Company |
0.27%
|
281,822
|
$9,581,948 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.25%
|
265,495
|
$8,904,702 | — | 31 Mar 2025 |
Institutional Holders of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) as of Q2 2025
As of 30 Jun 2025,
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) was held by
220 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
104,559,713 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, BlackRock, Inc., Driehaus Capital Management LLC, WELLINGTON MANAGEMENT GROUP LLP, PRICE T ROWE ASSOCIATES INC /MD/, FARALLON CAPITAL MANAGEMENT LLC, EcoR1 Capital, LLC, JANUS HENDERSON GROUP PLC, and STATE STREET CORP.
This page lists
220
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
225
Q2 2025 holders
220
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.